10-Q: Cibus Inc. Reports Q1 2025 Results, Highlights Regulatory Progress and Platform Development

Cibus Inc. announced its Q1 2025 financial results, showcasing advancements in its RTDS technology and regulatory approvals, while also reporting a net loss of $49.4 million and expressing substantial doubt about its ability to continue as a going concern.

Summary

• Cibus Inc. reported a net loss of $49.4 million for the three months ended March 31, 2025.
• Revenue for the quarter was $1.0 million, an increase of $0.5 million compared to the same period in 2024.
• Research and development expenses decreased slightly to $11.8 million.
• Selling, general, and administrative expenses increased to $9.9 million, primarily due to a $3.0 million estimated litigation liability.
• The company recognized a goodwill impairment of $21.0 million.
• Cibus highlighted regulatory progress, including the first authorization for planting gene-edited rice in California and positive regulatory developments in Ecuador.
• The company is actively engaging with prospective customers in geographies where rice is cultivated globally.
• Cibus is positioned at an important inflection point in the agricultural industry with regulatory progress advancing globally, the company's Rice traits moving into customer germplasm, and its disease resistance program showing remarkable results.
• The company issued 4,340,000 shares of its Class A Common Stock and pre-funded warrants to purchase 4,700,000 shares of Class A Common Stock in a registered direct offering in January 2025, raising approximately $21.4 million in net proceeds.
• The company's auditors have raised substantial doubt about its ability to continue as a going concern.

Sentiment

Score: 3

Explanation: The document presents a mixed picture. While there are positive developments in regulatory approvals and platform development, the significant net loss, goodwill impairment, and going concern warning weigh heavily on the overall sentiment.

Positives

• Revenue increased by $0.5 million compared to the same quarter last year.
• The company achieved key regulatory milestones in the United States and Ecuador.
• Cibus established production standards for its proprietary RTDS gene editing process across its Rice and Canola platforms.
• The company successfully edited Soybean cells for its HT2 trait, achieving sufficiently high editing rates to enable expanded platform development.
• The company raised $21.4 million through a registered direct offering in January 2025.

Negatives

• The company reported a net loss of $49.4 million for the quarter.
• The company recognized a goodwill impairment of $21.0 million.
• The company's auditors have raised substantial doubt about its ability to continue as a going concern.
• The company has an accumulated deficit of $778.1 million as of March 31, 2025.
• The company accrued an estimate of $3.0 million for litigation liability.

Risks

• The company's need for additional near-term funding to finance its activities and challenges in obtaining additional capital on acceptable terms, or at all.
• Changes in expected or existing competition.
• Challenges to the company's intellectual property protection and unexpected costs associated with defending intellectual property rights.
• Increased or unanticipated time and resources required for the company's platform or trait product development efforts.
• The company's reliance on third parties in connection with its development activities and for commercialization.
• Challenges associated with the company's ability to effectively license its productivity traits and sustainable ingredient products.
• The risk that farmers do not recognize the value in germplasm containing the company's traits or that farmers and processors fail to work effectively with crops containing the company's traits.
• Delays or disruptions in the company's platform or trait product development efforts.
• Challenges that arise in respect of the company's production of high-quality plants and seeds cost-effectively on a large scale.
• The company's dependence on distributions from Cibus Global to pay taxes and cover its corporate and overhead expenses.
• Regulatory developments that disfavor or impose significant burdens on gene editing processes or products.
• Delays and uncertainties regarding regulatory developments in the European Union.
• The company's ability to achieve commercial success.
• Commodity prices and other market risks facing the agricultural sector.
• Technological developments that could render the company's technologies obsolete.
• Impacts of the company's headcount reductions and other cost reduction measures, which may include operational and strategic challenges.
• Changes in macroeconomic and market conditions, including inflation, supply chain constraints, and rising interest rates, and economic volatility and uncertainty arising from dynamic trade policies, including tariffs and retaliatory tariffs, and market reactions to such policies.
• Dislocations in the capital markets and challenges in accessing liquidity and the impact of such liquidity challenges on the company's ability to execute on its business plan.
• The company's assessment of the period of time through which its financial resources will be adequate to support operations.

Future Outlook

The company anticipates that it will continue to generate losses for the next several years and will need to raise additional capital to support its business plans to continue as a going concern within one year after the date that these financial statements are issued.

Industry Context

The report highlights the increasing global regulatory support for gene editing, positioning Cibus at an important inflection point in the agricultural industry.

Comparison to Industry Standards

• The document does not contain specific comparisons to industry standards.
• The document does not contain specific comparisons to comparable companies.
• The document does not contain specific comparisons to comparable projects.
• The document does not contain specific comparisons to comparable results.

Management Changes

Legal Proceedings

• Based on an unexpected recent decision from the Ninth Circuit Court of Appeals, the Company has accrued an estimate of $3.0 million for litigation liability.

Related Party Transactions

• On December 31, 2014, Cibus Global entered into a Warrant Transfer and Exchange Agreement (Warrant Exchange Agreement) and a related Intellectual Property Security Agreement, pursuant to which certain investors, including certain directors of the Company and entities affiliated with directors of the Company (collectively, Royalty Holders), exchanged warrants issued by Cibus Global in previous financing transactions, for the right to receive future royalty payments (Royalty Payments).

Stakeholder Impact

• Shareholders face potential dilution and increased risk due to the company's need for additional capital and the going concern warning.
• Employees may be affected by potential cost reduction measures and organizational restructuring.
• Customers and partners may be impacted by potential delays or scaling back of operations.
• Creditors face increased risk due to the company's financial instability.

Next Steps

• The company will continue to develop its pipeline of productivity traits.
• The company will continue to pursue commercialization activities.
• The company will continue to seek government or other third-party funding.
• The company will continue to pursue public or private equity or debt financings.

Key Dates

Keywords

Cibus, gene editing, RTDS, plant traits, financial results, regulatory approvals, going concern, common stock, warrants, registered direct offering, Rice, Canola, Soybean